Sorafenib in Patients with Hepatopulmonary Syndrome (SHPS): A Double-Blind Randomized Clinical Trial
Study for patients with Hepatopulmonary syndrome (SHPS) using trial drug (Sorafenib)
Sponsor: National Heart Lung and Blood Institute
Enrolling: Male and Female Patients
Study Length: 4 Months
Clinic Visits: 8
IRB Number: AAAM9201
U.S. Govt. ID: NCT02021929
Contact: Theresa Lukose: 212-305-3839 / tt2103@columbia.edu
Additional Study Information: The purpose of this study is to determine the safety and effects of a drug, sorafenib in adults diagnosed with hepatopulmonary syndrome (HPS). The study will evaluate how well the drug is tolerated and its effect on the level of oxygen in the blood and the function of the lung vessels. Participants will be randomly assigned to receive either sorafenib or a placebo.
This study is closed
Investigator
Robert Brown, MD, MPH
Do You Qualify?
Are you currently enrolled in a clinical trial? Yes No
Do you currently have hepatic encephalopathy? Yes No
Are you currently taking Coumadin? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Theresa Lukose
tt2103@columbia.edu
212-305-3839
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE